Pharmacogenetic aspects of antithrombotic therapy

S. A Belkov; Белков С. А; V. I Khrupkin; Хрупкин В. И; D. A Sychev; Сычев Д. А; A. A Danko; Данько А. А; A. A Sagirova; Сагирова А. А; R. E Kazakov; Казаков Р. Е; A. O Danko; Данько А. О

doi:10.17816/RMMJ74126

Pharmacogenetic aspects of antithrombotic therapy

作者: Belkov S.A¹, Khrupkin V.I¹, Sychev D.A¹, Danko A.A¹, Sagirova A.A¹, Kazakov R.E¹, Danko A.O¹
隶属关系:
期: 卷 336, 编号 2 (2015)
页面: 55
栏目: Articles
URL: https://journals.eco-vector.com/0026-9050/article/view/74126
DOI: https://doi.org/10.17816/RMMJ74126
ID: 74126

如何引用文章

全文:

开放存取

##reader.subscriptionAccessGranted##
受限制的访问

订阅存取

详细
全文:
作者简介
参考
补充文件
统计

详细

In a study of 52 patients with coronary heart disease, taking warfarin, it was determined that a genetically caused increased haemorrhage risk occurred in 38,5% of cases. The authors provide recommendations concerning the dosage of warfarin: starter, saturating and maintenance doses.